ReproGLIO

ReproGLIO – Pioneer TF-based Reprogramming to Intercept Pediatric Malignant Entities

Overview

Pediatric brain tumors of glial origin are invariably lethal. These aggressive malignancies exhibit extensive inter-patient and intra-tumoral heterogeneity, with tumor cells existing in multiple dynamic epigenetic and transcriptional states. Current treatments remain ineffective, with most patients succumbing within two years after diagnosis. ReproGLIO aims to induce fate conversion of tumor cells into terminally differentiated, non-proliferative neurons by direct lineage reprogramming, as a novel strategy to restrain cell state transitions, restrict proliferation and invasion, and ultimately reduce tumor growth and mortality.

Project leader

Christophe Heinrich, head of the « Cellular Reprogramming in the Brain » team at the Centre de Recherche en Neurosciences de Lyon (CRNL), CNRS UMR5292, Inserm U1028, Lyon 1 University.

Direct lineage reprogramming within the brain (CRNL, Lyon)

Research team

Marie Castets (CRCL, Lyon)

Pediatric oncology and pediatric tumor modeling.

Rita Khoueiry (IARC, Lyon)

Brain tumor epigenetics.

Jean-Baptiste Alberge (Gustave Roussy, Paris)

Computational biology & bioinformatics.

Key objectives

Building on our previous achievements and uniquely combining complementary expertise, we follow a stepwise strategy spanning three integrated work packages:

  1. To reprogram tumor cells into neurons across the oncogenic trajectory in vitro

Using engineered pre-neoplastic models and patient-derived organoids across disease stages, we identify factors enabling efficient neuronal conversion of the distinct tumor cell states.

  1. To reconstruct and engineer cell fate trajectories during neuronal conversion of glioma cells

Using single-cell multiomics, we dissect the mechanistic basis of tumor-to-neuron conversion to:

  1. To uncover the therapeutic potential of tumor cell reprogramming in preclinical models

Resources deployed

Expected results

We expect to show that reprogramming glioma cells into stable, post mitotic neurons:

ReproGLIO will also reveal if forcing neuronal reprogramming of cells at pre-neoplastic stages prevents tumor development and enables disease interception.

Together, ReproGLIO will uncover the translational potential of tumor-to-neuron reprogramming as a transformative therapeutic strategy for pediatric brain cancer interception.


Les autres projets PEPR